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Abstract
Background/Aim. Results of studies which have proved
an increased inflammatory activity in diabetes type 1, have
been published over recent years. One of possible mecha-
nisms that are used to explain chronic inflammation in
diabetes is the state of hyperglycemia leading to the en-
hanced synthesis of glycosylation end products (AGEs)
which activate macrophages, increase the oxidative stress
and affect the synthesis of interleukins (IL-1, IL-6), tumor
necrosis factor-α (TNF-α) and C-reactive protein (CRP).
The aim of the study was to determine the inflammatory
markers (CRP, IL-6, TNF-α) in patients with diabetes type
1 and to establish their correlation with glucoregulation
parameters and other cardiovascular risk factors as well as
to compare them with the healthy controls. Methods. The
study included 76 patients with diabetes type 1 and 30
healthy controls. We determined values of inflammatory
markers (CRP, IL-6, TNF-α) and glucoregulation parame-
ters (fasting glucose HbA1c). Results. The values of CRP
(p = 0.014), IL-6 (p = 0.020) and TNF-α (p = 0.037) were
statistically significantly higher in the diabetic patients than
in the healthy controls. There was a positive correlation
between CRP with postprandial glycemia (p = 0.004); the
multivariate regression analysis revealed a statistically sig-
nificant correlation between CRP and age (p = 0.001),
smoking (p  =  0.055), fasting glucose (p = 0.021)  and  tri-
glycerides (p = 0.048) as well as between IL-6 and LDL-
cholesterol (p = 0,009). No statistically significant correla-
tions were found between glycosilated hemoglobin
(HbA1c) and the inflammatory markers (CRP, IL-6 and
TNF-α). Conclusion. The patients with type 1 diabetes
were found to have a low level of inflammatory activity
manifested by the increased values of CRP, IL-6 and
TNF-α.
Key words:
diabetes mellitus, type 1; blood glucose; c-reactive
protein; interleukin-6; tumor necrosis factor-alpha;
sensitivity and specificity.
Apstrakt
Uvod/Cilj. Poslednjih godina objavljeni su rezultati studija
koje su dokazale da i kod dijabetesa tipa 1 postoji povećana in-
flamatorna aktivnost. Jedan od mogućih mehanizama kojima se
pokušava objasniti hronična inflamacija kod dijabetesa je stanje
hiperglikemije s posledičnim povećanjem sinteze krajnjih pro-
dukata glikozilacije (AGE), koji aktiviraju makrofage, poveća-
vaju oksidativni stres i utiču na sintezu interleukina (IL-1, IL-
6), tumor nekrozis faktora-α (TNF-alfa) i C-reaktivnog proteina
(CRP). Cilj rada bio je određivanje inflamatornih markera
(CRP, IL-6, TNF-alfa) kod bolesnika sa dijabetesom tipa 1, te
utvrđivanje njihove povezanosti sa parametrima glikoregulacije
i drugim kardiovaskularnim faktorima rizika, kao i njihovo po-
ređenje sa vrednostima kontrolne grupe zdravih ispitanika.
Metode. Ispitivanje je sprovedeno kao unakrsna studija prese-
ka na 76 bolesnika sa dijabetesom tipa 1, dok je kontrolnu gru-
pu činilo 30 zdravih ispitanika. Određivani su markeri inflama-
cije (CRP, IL-6, TNF-alfa)  i parametri glikoregulacije (glikemi-
ja, HbA1c).  Rezultati. Vrednosti CRP (p = 0,014),  IL-6
(p = 0,020), TNF-α (v 0,037) bile su statistički značajno više u
grupi dijabetesnih bolesnika nego u kontrolnoj grupi zdravih
osoba. Utvrđeno je postojanje statistički značajne pozitivne ko-
relacije CRP sa glikemijom postprandijalno (p = 0,004), dok je
primenom multivarijantne regresione analize nađena statistički
značajna korelacija CRP sa godinama života (p = 0,001), puše-
njem (p = 0,055), glikemijom našte (p = 0,021) i trigliceridima
(p = 0,048), a istom metodom i statistički značajna korelacija
IL-6 sa LDL-holesterolom (p = 0,009). Nisu nadjene statistički
značajne korelacije između HbA1c i inflamatornih markera
CRP, IL-6 i TNF-α. Zaključak. Kod bolesnika sa dijabetesom
tipa 1, u odnosu na zdrave ispitanike, postoji inflamatorna akti-
vnost niskog stepena koja se ogleda kroz povišene vrednosti
CRP, TNF-alfa i IL-6. Od parametara glikoregulacije izdvojile
su se glikemija našte i postprandijalno koje pozitivno korelišu sa
vrednostima CRP, dok nisu nađene statistički značajne korela-
cije sa HbA1c.
Ključne reči:
dijabetes melitus, insulin-zavisni; glikemija; c-reaktivni
protein; interleukin-6; faktor nekroze tumora;
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Introduction
Numerous epidemiological and clinical studies as well
as those performed on autopsy material have proved that ath-
erogenesis develops earlier in patients with diabetes type 1
than in healthy population, thus making the progression of
cardiovascular complications far more expressed
 1, 2. It is per-
fectly clear that atherogenesis is a chronic inflammatory pro-
cess and this fact has been corroborated by results of numer-
ous studies which have found increased values of inflamma-
tory markers such as C-reactive protein (CRP), interleukin-6
(IL-6) and tumor necrosis factor alpha (TNF-α). Many stud-
ies, whose results have been published in recent years, have
shown that diabetes type 1 is also associated with the in-
creased inflammation 
2. One of the mechanisms which might
explain chronic inflammation in diabetes is the condition of
hyperglycemia, which leads to an increased synthesis of ad-
vanced glycation endproducts (AGEs) resulting from the in-
teraction of glucose in high concentrations with structural
and circulating proteins. Advanced glycation end products
are considered to activate macrophages, increase the oxida-
tive stress and affect the synthesis of IL-1, IL-6, TNF-α and
CRP. Of all the proteins of the acute phase and plasma in-
flammatory markers, C-reactive protein (CRP) has been most
widely studied and it is believed to have a very important
role in the endothelial dysfunction and the process of athero-
sclerosis. It is also considered to be one of the important and
independent predictors of future cardiovascular events.
Hepatocytes produce CPR as a response to the increased
level of IL-6, IL-1, TNF-α
 1–3, which is a sensitive infection
marker and it is produced as a systemic inflammatory re-
sponse to a local or systemic infection. It is widely used in
clinical setting to follow not only the disease course but also
the effects of the applied antiinflammatory and antibiotic
therapy
 3, 4. A high sensitivity C-reactive protein is used to
detect small changes of CRP levels associated with an in-
creased cardiovascular risk in healthy population 
5. Interleu-
kin 6 is an intercellular mediator and primary indicator of the
liver CPR 
6. Although it originates from T cells, other cells
such as macrophages, monocytes, smooth-muscle cells,
epithelial/endothelial/mesangial cells, fibroblasts, synovial
cells, osteoblasts as well as chondrocytes may also be pro-
voked to produce IL-6 
7. An increased IL level is present in
many autoimmune diseases, such as rheumatoid arthritis,
systemic lupus erythematosus as well as in diabetes of both
types 1 and 2
 8–10. The circulating IL-6 stimulates hypotha-
lamic-hypophyseal axis whose activation is responsible for
the central obesity, hypertension and insulin resistance
 11, 12.
TNF-α is a pleiotropic cytokine produced by various cells
such as macrophages, endothelial and smooth-muscle cells.
It is one of the most important cytokines in the intercellular
communication 
13. Recent studies have proved that TNF-α
activation may directly or indirectly affect pathogenesis and
induce macrovascular complications in diabetes as well as
atherosclerotic vascular lesions
 14, 15. It has a major role in the
amplification of inflammatory cascade. TNF-α also plays a
certain role in damaging the pancreas beta cells by being re-
sponsible not only for diabetes type 1 pathogenesis but for
the development of insulin resistance associated with obesity
and diabetes type 2, as well
 15, 16.
The aim of the study was to analyse the level of in-
flammatory markers CRP, IL-6 and TNF-α in a group of pa-
tients with diabetes type 1 and a group of healthy controls
and to correlate their values with the parameters of gly-
coregulation such as glycosylated hemoglobin (HbA1c),
fasting and postprandial glycemia as well as lipid and lipo-
protein status.
Methods
This cross-sectional study was performed on a group of
106 subjects, of whom 76 were the patients with diabetes
type 1 and 30 were the healthy controls. The study group
consisted of the patients with diabetes type 1, which had
been diagnosed before they were 36 years of age and who
were on insulin therapy in the first year after the diagnosis
had been made. They either visited day hospital for diabetes
or were hospitalized in the Department of Endocrinology,
Clinical Center of Vojvodina. The group of healthy controls
consisted of 30 subjects of both sexes, of approximately the
same age, normally nourished and without other risk factors
for atherosclerosis.
The following data were taken for both groups of sub-
jects: sex, age, length of the disease, age when the disease
was diagnosed, smoking habit and family medical history.
To assess the state of metabolic regulation in diabetes the
values of fasting glycemia were taken 2 hours after breakfast
as well as the values of HbA1c; when the latter were less
than 7.5% they pointed to the satisfactory glucoregulation in
diabetes, whereas when they were over 7.5%, glucoregula-
tion was considered unsatisfactory. Values of total choles-
terol, LDL-cholesterol, HDL-cholesterol and triglycerides
were measured to analyze the lipid and lipoprotein status.
The nourishment status was assessed on the basis of anthro-
pometric measurements, body mass, body height and body
mass index (BMI). The waist was measured in centimeters
and the recommended values according to the IDF criteria 
17
were considered to be desirable: less than 80 cm for women
and less than 94 cm for men. The following inflammatory
markers were determined: serum fibrinogen concentrations,
CRP, IL-6 and TNF-α. The serum samples were kept at -
80ºC before being analyzed. C-reactive protein was deter-
mined by electrochemiluminescence, and the referral values
were from 0 to 5mg/L. TNF-α and IL-6 were determined in
the Laboratory for Immunology, Department of Nephrology
and Immunology, Clinical Center Vojvodina by commercial
ELISA plates according to the standard procedure recom-
mended by the manufacturer.
The collected data were processed by the methods of
descriptive and inferential statistics. The following was pre-
sented as the numerical characteristics: the arithmetic mean,
median, standard deviation and either the value range or the
interquartile range, depending on the data nature. Mean val-
ues of the numerical characteristics of the two groups were
compared by the t-test. Differences in the distribution of nu-
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groups were compared by the nonparametric Mann-Whitney
test and among three groups by the Kruskal-Wallis test. The
correlation of the two characteristics were examined by the
Spearman’s coefficient of correlation. Multivariate regres-
sion analysis was applied to determine the predictions and
correlations between dependent variables with independent
ones: the linear regression was used when the dependent
variable was continuous and the logistic regression model
was applied when the dependent variable was dichotomous
(binary).
Results
Table 1 shows the characteristics of the study and the
control group which did not differ in sex and age structure,
nourishment status, values of total cholesterol, HDL-
cholesterol, LDL-cholesterol and triglycerides. Not surpris-
ingly, the study group had statistically significantly higher
values of fasting glycemia (p = 0.000), postprandial glycemia
(p = 0.003) as well as the values of HbA1c (p = 0.000) com-
pared to the healthy controls. The values of CPR (p = 0.014),
IL-6 (p = 0.0200), TNF (p = 0.037) were statistically signifi-
cantly higher in the diabetic patients than in the healthy con-
trols. The average duration of diabetes in the group of dia-
betic patients was 20.01 years.
As shown in Table 2, the correlation between CRP and
postprandial glycemia was significant (p = 0.021) and posi-
tive. No significant correlation was found between fasting
glycemia and CRP, TNF-α, IL-6 nor between postprandial
glycemia and TNF-α and IL-6.
According to the HbA1c value, which was over 7.5% in
almost 87% of the patients (Table 3) it was concluded that
the study group of the diabetic patients had a poor metabolic
regulation. No statistically significant correlation was found
between HbA1c and CRP (p = 0.878), IL-6 (p = 0.249) and
TNF-α (p = 0.817).
When multiple linear regression was applied, the CRP
value was regarded as a dependent variable, and the rest of
the mentioned values were regarded as independent vari-
ables. The following variables were found to be significant
CRP predictors: age, smoking habit, fasting glycemia, tri-
glycerides; whereas sex, age, LDL-cholesterol and triglyc-
erides were significant for predicting IL-6 levels. All inde-
pendent variables shown in Table 4 (the reduced model)
were significantly correlated with the CRP value (F = 6.568,
p = 0.000) and IL-6 value (F = 3.121, p = 0.020).
Table 1
Characteristics of the study and the control group
Patients characteristics and parameters Study group (n = 76) Control group (n = 30) p
Sex (male/female) 32/44 12/18 0.899
Age (years) 35.24 ± 11.09 38.10 ± 12.97 0.454
BMI (kg/m
2) 23.67 ± 3.13 23.88 ± 2.49 0.843
Waist (desirable/risky) 60/16 18/12 0.182
Duration of DM (years)
Fasting glycemia (mmol/L)
20,01± 8,78
10.84 ± 4.84
/
4.87 ± 0.78 0.000
Postprandial glycemia (mmol/L) 11.30 ± 5.34 6.09 ± 0.47 0.003
HbA1c (%) 9.20 ± 1.71 5.55 ± 0.19 0.000
Total cholesterol (mmol/L) 5.22 ± 1.02 5.00 ± 0.38 0.488
HDL-cholesterol (mmol/L) 1.39 ± 0.35 1.39 ± 0.25 0.978
LDL-cholesterol (mmol/L) 3.27 ± 0.86 3.16 ± 0.26 0.675
Triglycerides (mmol/L) 0.92 (0.69–1.49) 0.92 (0.64–1.24) 0.716
CRP (mg/L) 1.20 (0.70–2.78) 0.50 (0.10–1.40) 0.014
IL-6 (pg/mL) 0.76 (0.35–1.25) 0.15 (0.00–0.91) 0.020
TNF-α (pg/mL) 0.65 (0.22–1.70) 0.20 (0.00–0.45) 0.037
Data in Table 1 are shown as absolute numbers (the significance for χ
2 test) or ґ ± SD (the significance for t-test). Median (interquartile range) is
given for triglycerides, inflammatory markers CRP, IL-6, TNF-α; the significance being for Mann-Whitney test
BMI – body mass index; HbA1c – glycosilated hemoglobin; CRP – C-reactive protein; IL-6 – interleukin-6; TNF-α – tumor necrosis factor α
Table 2
Correlation between the inflammatory marker values and fasting and postprandial glycemia (pp)
Coefficient glycemia Significance glycemia Markers
(fasting) (pp) (fasting) (pp)
CRP (mg/L) 0.131 0.265 0.261 0,021
IL-6 (pg/mL) 0.009 0.052 0.941 0.655
TNF-α (pg/mL) 0.176 0.206 0.131 0.076
CRP – C-reactive protein; IL-6 – interleukin-6; TNF-α – tumor necrosis factor α
Table 3
Correlation between CRP, IL-6, TNF-α and HbA1c
HbA1c (normal/increased) n Mean value Median SD p
CRP (mg/L) 10/66 2.01/2.26 1.25/1.20 2.04/2.75 0.878
IL- 6 (pg/mL) 10/66 0.74/1.28 0.50/0.79 0.70/1.55 0.249
TNF- α (pg/mL) 10/66 1.19/1.41 0.43/0.70 1.52/2.46 0.817
HbA1c – glycosilated hemoglobin; CRP – C-reactive protein; IL-6 – interleukin-6; TNF-α – tumor necrosis factor αVolumen 68, Broj 9 VOJNOSANITETSKI PREGLED Strana 759
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According to the obtained coefficient value it can be
stated that 31.9% of the changes were in the CRP level; 15%
of the changes in the values of IL-6 were explained by the
changes in values of independent variables from Table 4 (the
reduced model).
Discussion
Inflammation and oxidative stress play an important role
in the process of atherosclerosis; therefore, patients having dia-
betes type 1 are at higher risk for cardiovascular morbidity and
mortality. Although the majority of studies on these problems
dealt with diabetes type 2, recently published results have indi-
cated that there is an increased inflammatory activity in patients
having diabetes type 1, as well
 1, 2, 7, 11, 13, 15. The afore mentioned
has been corroborated by our results as well, which have shown
that patients with diabetes type 1 have a low degree of an in-
flammatory activity, which is reflected through the increased
values of CRP, TNF-α, IL-6. All of the studied inflammatory
markers, CRP, IL-6, TNF-α were significantly higher in the
diabetic patients than in the healthy controls. These results are
in accordance with the results of studies which have found in-
creased CRP in adults having diabetes type 1
 11, 12. Although the
mechanism of CRP rise is not completely clear, it seems to be
associated with the activation of macrophages, increased oxi-
dative stress and induction of cytokines. In their study, Okano
et al. 
18 observed statistically significantly higher CRP values in
patients with diabetes type 1 than in the healthy controls. Their
study did not show statistically significant differences in age,
the nourishment status index, values of LDL-cholesterol, HDL-
cholesterol and triglycerides between the diabetic patients and
healthy controls. This study has clearly shown that the in-
creased level of hs-CRP correlated with the early stage of ca-
rotid atherosclerosis in young patients having diabetes type 1,
measured through the level of carotid intima-media thick-
ness 
18. Alexandraki et al. 
19 found higher values of CRP, IL-6
and TNF-α in the patients with diabetes type 1 than in the
healthy controls. However, the values of the above mentioned
inflammatory markers were lower than in the group of patients
having diabetes type 2.
Chronic hyperglycemia results in advanced glycation
end products (AGE), which activate macrophage, increase
the oxidative stress and affect the synthesis of IL-6, IL-1,
TNF-α and CRP. A great number of studies has clearly
shown a significant correlation between HbA1c, fasting and
postprandial glycemia and the inflammatory markers CRP,
IL-6 and TNF-α 
19–25. A positive correlation was found be-
tween the values of CRP and postprandial glycemia and the
one with fasting glycemia was determined by the multivari-
ate regression analysis. These results are in accordance with
the most recent opinions about the importance of postpran-
dial hyperglycemia in the development of inflammation and
chronic complications. Postprandial hyperglycemia is a very
frequent phenomenon in patients with both type 1 and type 2
diabetes, and it can be also found in patients with well-
regulated diabetes, assessed on the basis of HbA1c values 
18–
20. Postprandial hyperglycemia increases the oxidative stress
and together with hypertriglyceridemia increases the produc-
tion of intercellular adhesion molecules (ICAM) and vascu-
lar cell adhesion molecules (VCAM), E-selectin as a marker
of the endothelial dysfunction, thus affecting the increased
production of inflammatory cytokines 
22–25. Our results did
not show a significant correlation between the inflammatory
markers (CRP, IL-6, TNF-α) and the values of HbA1c. Such
findings may be explained by the fact that almost 87% of the
patients were metabolically unregulated, two fifth of them
having HbA1c values over 9.5%. These results can be com-
pared with the results of some studies which have also failed
to show the existence of a significant correlation between in-
flammatory markers and HbA1c
 10, 20, thus making it clear that
factors other than hyperglycemia affect inflammation and
endothelial dysfunction in diabetes.
Dyslipidemia in diabetes type 1 is mostly the result of a
poor metabolic regulation of the diseases, with the conse-
quent increase in triglycerides and decrease in HDL-
cholesterol 
26. Besides, the development and progression of
nephropathy in diabetes type 1 contribute to the development
of dyslipidemia together with the increase in the total cho-
lesterol, LDL-cholesterol, total triglycerides and the decrease
in the protective HDL2-cholesterol
 26, 27. At the same time,
Table 4
Linear regression model with dependent variables IL-6 and CRP
Reduced model for IL-6 Reduced model for CRP Independent variables
Coefficient tp Coefficient tp
Sex -0.207 -1.698 0.094
Age -0.010 -1.971 0.053 0.018 3.343 0.001
Duration of diabetes
Before/after puberty
Smoking habit 0.248 1.955 0.055
BMI
Waist
Fasting glycemia 0.039 2.950 0.004
Postprandial glycemia
HbA1c
LDL-cholesterol 0.176 2.680 0.009
HDL-cholesterol
Triglycerides -0.141 -1.869 0.066 0.163 2.008 0.048
R
2 15% 31,9%
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hyperlipoproteinemia, and particularly hypercholesterolemia,
can be an important risk factor for the progression of diabetic
nephropathy, as it has been proved in many studies on pa-
tients with diabetes type 1 
28–30. No statistically significant
differences in the values of total cholesterol, HDL choles-
terol and triglycerides were found between the study group
of diabetic patients and the healthy controls. Such results are
in accordance with the studies which failed to prove the ex-
istence of statistically significant differences in the values of
lipid parameters between the healthy subjects and the pa-
tients with diabetes type 1
 31–33.
A statistically significant correlation between CRP and
triglycerides as well as between IL-6 with triglycerides and
LDL-cholesterol was found by the multivariate regression
analysis. The same analysis failed to find any correlations
between TNF-α and inflammatory markers. Eurodiab
study 
34 has clearly shown a correlation between the values
of triglycerides and HDL cholesterol with inflammatory
markers, and it has been confirmed in the healthy population,
as well. They have not confirmed a statistically significant
correlation between LDL and inflammatory markers
 34, 35. In
their study, Ladeia et al. 
36 found a significant correlation
between CRP and the values of triglycerides and the ratio of
triglycerides/HDL. The study did not show a correlation of
CRP and other lipid parameters. Increased values of TNF-α
in patients with diabetes type 1 and its role as an inflamma-
tory cytokine in the pathogenesis of diabetic nephropathy
and other micro- and macrovascular complications have been
confirmed by numerous studies
 36–38. Our study also con-
firmed increased values of TNF-α in the diabetic patients.
However, no correlation was found between TNF-α and lipid
and lipoprotein parameters, that being in accordance with the
results of some other authors
 39, 40.
Conclusion
In the patients with diabetes type 1 there is a low degree
of an inflammatory activity which is manifestated by higher
values of CRP, TNF-α and IL-6 compared to the healthy
controls. Future prospective studies should prove the impor-
tance of inflammation in the pathogenesis of chronic micro-
and macrovascular complications in the population of dia-
betic patients, as well.
Correlations of certain inflammatory markers with glu-
coregulation parameters, lipid parameters and hypertension
offer the possibility of therapeutic modification of inflam-
mation in diabetes indirectly by improving glucoregulation,
treating dyslipidemias and hypertension.
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